StoxCaplin Point Laboratories vs Poly Medicure: share price & financials comparison
NSE: CAPLIPOINT vs POLYMED · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Caplin Point Laboratories vs Poly Medicure at a glance
Caplin Point Laboratories (CAPLIPOINT) has a market capitalisation of ₹18,107 Cr, against ₹16,342 Cr for Poly Medicure (POLYMED). Over the past year Caplin Point Laboratories has returned +17.9%, compared with -18.1% for Poly Medicure. On valuation, Caplin Point Laboratories trades at a lower P/E of 27.2 versus 51.3. Caplin Point Laboratories earns a higher return on equity (18.6% vs 9.8%). Caplin Point Laboratories comes out ahead on size, valuation, profitability, financial health, momentum and technicals. Poly Medicure comes out ahead on growth. Across the scored metrics below, Caplin Point Laboratories leads on 13 and Poly Medicure on 5. On StoxGud's 10-point checklist, Caplin Point Laboratories scores 9/10 and Poly Medicure scores 6/10.
| Metric | Caplin Point Laboratories | Poly Medicure |
|---|---|---|
| Size | ||
| Market cap | ₹18,107 Cr | ₹16,342 Cr |
| Revenue (latest FY) | ₹2,187 Cr | ₹1,875 Cr |
| Net profit (latest FY) | ₹641 Cr | ₹322 Cr |
| Valuation | ||
| P/E | 27.2 | 51.3 |
| P/B | 5.05 | 5.00 |
| Dividend yield | 0.25% | 0.22% |
| Profitability | ||
| Return on equity | 18.6% | 9.8% |
| Net profit margin | 29.1% | 14.9% |
| Operating margin | 34.8% | 22.7% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | +30.8% |
| Net profit growth (YoY) | +15.8% | +3.6% |
| Revenue CAGR (multi-year) | +15.6% | +19.0% |
| Financial health | ||
| Debt to equity | 0.00 | 0.12 |
| Momentum | ||
| 1-month return | -10.1% | -0.2% |
| 1-year return | +17.9% | -18.1% |
| 3-year CAGR | +29.7% | +5.5% |
| 5-year CAGR | +22.9% | +12.2% |
| 10-year CAGR | +20.1% | +23.6% |
| Distance from 52W high | -16.9% | -21.9% |
| Technicals | ||
| RSI (14) | 59 | 52 |
| Price vs 200-day avg | +9.5% | +4.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Caplin Point Laboratories | Poly Medicure |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Caplin Point Laboratories or Poly Medicure?
Caplin Point Laboratories has a market cap of ₹18,107 Cr and Poly Medicure has a market cap of ₹16,342 Cr as of 06 Nov 2026.
Which has a lower P/E, Caplin Point Laboratories or Poly Medicure?
Caplin Point Laboratories has the lower P/E: Caplin Point Laboratories trades at 27.2 and Poly Medicure at 51.3.
Which gave better returns in the last year, Caplin Point Laboratories or Poly Medicure?
Caplin Point Laboratories did better: Caplin Point Laboratories returned +17.9% and Poly Medicure returned -18.1% over one year.
Is Caplin Point Laboratories or Poly Medicure a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Caplin Point Laboratories scores 9/10 and Poly Medicure scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.